^
Association details:
| Biomarker: | ALK I1171N |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
523 - Lorlatinib Induces Rapid Response in Chemotherapy-Refractory and Alectinib-Refractory Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma.
Published date:
02/11/2022
Excerpt:
A 29-year-old male had fever, splenomegaly, and bone pain….A plasma cell-free DNA [cfDNA] next-generation sequencing assay detected the ALK I1171N mutation that confers resistance to alectinib but is sensitive to lorlatinib. On day +152, plasma cfDNA genotyping showed no ALK mutation. Bone marrow biopsy showed no lymphoma and negative ALK mutation analysis. The patient is tolerating lorlatinib well.
